Literature DB >> 26100084

Rhinovirus infection interferes with induction of tolerance to aeroantigens through OX40 ligand, thymic stromal lymphopoietin, and IL-33.

Amit K Mehta1, Wei Duan1, Astrid M Doerner2, Suzanne L Traves3, David H Broide4, David Proud3, Bruce L Zuraw2, Michael Croft5.   

Abstract

BACKGROUND: Rhinovirus infection at an early age has been associated with development of asthma, but how rhinovirus influences the immune response is not clear.
OBJECTIVE: Tolerance to inhaled antigen is mediated through induction of regulatory T (Treg) cells, and we examined whether rhinovirus infection of the respiratory tract can block airway tolerance by modulating Treg cells.
METHODS: The immune response to intranasal ovalbumin in mice was assessed with concomitant infection with RV1B, and the factors induced in vivo were compared with those made by human lung epithelial cells infected in vitro with RV16.
RESULTS: RV1B infection of mice abrogated tolerance induced by inhalation of soluble ovalbumin, suppressing the normal generation of forkhead box protein 3-positive Treg cells while promoting TH2 cells. Furthermore, RV1B infection led to susceptibility to asthmatic lung disease when mice subsequently re-encountered aeroantigen. RV1B promoted early in vivo expression of the TNF family protein OX40 ligand on lung dendritic cells that was dependent on the innate cytokine thymic stromal lymphopoietin (TSLP) and also induced another innate cytokine, IL-33. Inhibiting each of these pathways allowed the natural development of Treg cells while minimizing TH2 differentiation and restored tolerance in the face of RV1B infection. In accordance, RV16 infection of human lung epithelial cells upregulated TSLP and IL-33 expression.
CONCLUSIONS: These results suggest that infection of the respiratory epithelium with rhinovirus can antagonize tolerance to inhaled antigen through combined induction of TSLP, IL-33, and OX40 ligand and that this can lead to susceptibility to asthmatic lung inflammation.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asthma; OX40 ligand; RV16; RV1B; epithelial cell; peripherally induced regulatory T cell; thymic stromal lymphopoietin

Mesh:

Substances:

Year:  2015        PMID: 26100084      PMCID: PMC4684822          DOI: 10.1016/j.jaci.2015.05.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  55 in total

1.  Inducible CD4+LAP+Foxp3- regulatory T cells suppress allergic inflammation.

Authors:  Wei Duan; Takanori So; Amit K Mehta; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

Authors:  I Gramaglia; A D Weinberg; M Lemon; M Croft
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.

Authors:  Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes
Journal:  N Engl J Med       Date:  2014-05-20       Impact factor: 91.245

4.  Innate signals from Nod2 block respiratory tolerance and program T(H)2-driven allergic inflammation.

Authors:  Wei Duan; Amit K Mehta; Joao G Magalhaes; Steven F Ziegler; Chen Dong; Dana J Philpott; Michael Croft
Journal:  J Allergy Clin Immunol       Date:  2010-11-04       Impact factor: 10.793

5.  Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment.

Authors:  Takanori So; Jianxun Song; Katsuji Sugie; Amnon Altman; Michael Croft
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-24       Impact factor: 11.205

6.  Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses.

Authors:  G P Rakes; E Arruda; J M Ingram; G E Hoover; J C Zambrano; F G Hayden; T A Platts-Mills; P W Heymann
Journal:  Am J Respir Crit Care Med       Date:  1999-03       Impact factor: 21.405

7.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

Authors:  P R Rogers; J Song; I Gramaglia; N Killeen; M Croft
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

8.  Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice.

Authors:  Koubun Yasuda; Taichiro Muto; Tatsukata Kawagoe; Makoto Matsumoto; Yuki Sasaki; Kazufumi Matsushita; Yuko Taki; Shizue Futatsugi-Yumikura; Hiroko Tsutsui; Ken J Ishii; Tomohiro Yoshimoto; Shizuo Akira; Kenji Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

9.  TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells.

Authors:  Atsushi Kato; Silvio Favoreto; Pedro C Avila; Robert P Schleimer
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

10.  TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.

Authors:  Tomoki Ito; Yui-Hsi Wang; Omar Duramad; Toshiyuki Hori; Guy J Delespesse; Norihiko Watanabe; F Xiao-Feng Qin; Zhengbin Yao; Wei Cao; Yong-Jun Liu
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

View more
  19 in total

1.  Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection.

Authors:  A K Mehta; T Doherty; D Broide; M Croft
Journal:  Allergy       Date:  2018-03-01       Impact factor: 13.146

Review 2.  Advances in environmental and occupational disorders in 2016.

Authors:  William J Sheehan; Jonathan M Gaffin; David B Peden; Robert K Bush; Wanda Phipatanakul
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

3.  IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs.

Authors:  Chien-Chang Chen; Takao Kobayashi; Koji Iijima; Fan-Chi Hsu; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2017-02-11       Impact factor: 10.793

Review 4.  Pathogenic CD4+ T cells in patients with asthma.

Authors:  Lyndsey M Muehling; Monica G Lawrence; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2017-04-22       Impact factor: 10.793

5.  IL-33 Signaling in Lung Injury.

Authors:  Jing Chang; Yue-Feng Xia; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  Transl Perioper Pain Med       Date:  2016

6.  Rhinovirus Infection of ORMDL3 Transgenic Mice Is Associated with Reduced Rhinovirus Viral Load and Airway Inflammation.

Authors:  Dae Jin Song; Marina Miller; Andrew Beppu; Peter Rosenthal; Sudipta Das; Maya Karta; Christine Vuong; Amit Kumar Mehta; Michael Croft; David H Broide
Journal:  J Immunol       Date:  2017-08-21       Impact factor: 5.422

Review 7.  Effects of Allergic Sensitization on Antiviral Immunity: Allergen, Virus, and Host Cell Mechanisms.

Authors:  Regina K Rowe; Michelle A Gill
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.919

8.  Thymic stromal lymphopoietin, IL-33, and periostin in hospitalized infants with viral bronchiolitis.

Authors:  María Luz García-García; Cristina Calvo; Ana Moreira; José Antonio Cañas; Francisco Pozo; Beatriz Sastre; Sergio Quevedo; Inmaculada Casas; Victoria Del Pozo
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 9.  Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma.

Authors:  Katherine H Restori; Bharat T Srinivasa; Brian J Ward; Elizabeth D Fixman
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

10.  Mesenchymal stem cells inhibit T cell activation by releasing TGF-β1 from TGF-β1/GARP complex.

Authors:  Jian Niu; Wang Yue; Zhu Le-Le; Liu Bin; Xin Hu
Journal:  Oncotarget       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.